Evolus Q1 revenue $68.5M (+15.5% YoY); reaffirms FY2025 guidance; Evolysse launch strong

Evolus, Inc.

2025-Q1 EPS reported -$0.30 revenue$68,522,000

Q1 global net revenue $68.5M, up 15.5% from Q1 2024 on higher volumes and market share gains.
GAAP operating loss $15.2M; non-GAAP operating loss $5.5M (excludes stock-based comp, depreciation).
Reaffirmed FY2025 revenue guidance $345M to $355M, representing 30-33% growth over 2024.
Evolysse HA filler launched April 2025; strong early adoption; expected 8-10% of 2025 revenue.
On track for positive non-GAAP operating income in Q4 2025 and full-year 2025; tariffs no impact.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.